Knowledge Transfer

BRI has successfully established itself as a major player in the global biotechnology arena and has continually helped to spearhead biotechnology developments in Hong Kong. Our research has resulted in a number of international patents, and collaborative industrial partnerships that have elevated our technological capabilities in drug development to a respectable level. A notable example is the collaboration between BRI and Geron Corporation, a NASDAQ-listed biopharmaceutical company, to identify anti-aging products using BRI’s expertise in TCM and Geron’s proprietary telomerase technology platform. BRI will continue to pursue excellence in biotechnology in years to come, thereby facilitating development of HKSAR’s competitiveness in this promising field.